Recent News

Rare Case of Acute Macular Neuroretinopathy in a Woman With CLL

AACR 2021: T-Cell Infusion Product Under Investigation in Resistant CLL

Concurrent Adenoid Cystic Carcinoma and CLL: Case Report

Response to Induction Therapy and Ofatumumab Consolidation in Patients With CLL

Identifying Prognostic Markers for Early-Stage CLL

Novel Agent Under Study in CLL: Dual Inhibitory Activity Reported

High-Risk CLL: GENUINE Trial of Ublituximab Plus Ibrutinib Versus Ibrutinib Alone

BTK Inhibitor and Cerebral Invasive Aspergillosis: Case Report in CLL

Toxicity and Treatment Discontinuation in CLL: U.S. Veterans Health Administration Study

Successful Addition of a New Treatment Arm to the Phase III FLAIR Trial in CLL

Subclinical Coagulopathy Associated With Obinutuzumab Infusion for CLL?

Preclinical Study of Combination Therapy for CLL: Avadomide Plus Checkpoint Inhibition

Case Report in CLL: Is Sclerouveitis an Off-Target Effect of Ibrutinib Treatment?

Blood Clots: New Adverse Event With First Infusion of Obinutuzumab for CLL?

Case Study: Personalized Low-Dose Immunotherapy for Poor-Prognosis CLL

Ibrutinib Versus Idelalisib Plus Rituximab in Resistant CLL

Blood Eosinophil Count and Prognosis in CLL

TCT 2021: Case of Accelerated-Phase CLL/SLL Relapsing as PTCL After Transplantation

TCT 2021: Update on Transplant Outcomes for CLL in Australasia

Case Report: CLL With Right Temporal Lobe Tumor

Reports of Rare Translocation in Chinese Patients With CLL

Using a Whole-Blood Loop Assay to Characterize Immune Response to Rituximab

COVID-19 and CLL: A Spanish Perspective

Pilot Study of Rituximab Biosimilar in Newly Diagnosed CLL

Novel STAT3 Inhibitor Under Study in CLL

Does Idelalisib Increase the Risk of Bleeding Events in Patients With CLL?

Lisocabtagene Maraleucel for Resistant CLL: Phase I Trial Update

Early Study of Lisocabtagene Maraleucel Plus Ibrutinib in Resistant CLL

FDA Brief: Rituximab Biosimilar Approved for Treatment of CLL

ASH 2020: 5-Year Update From MURANO on Venetoclax Versus Bendamustine in Resistant CLL

ASH 2020: Long-Term Update on Ibrutinib Plus Venetoclax in CLL

ASH 2020: PI3K Inhibitor Plus Monoclonal Antibody Versus Chemoimmunotherapy for CLL

ASH 2020: Early-Phase Study of Noncovalent BTK Inhibitor in CLL

ASH 2020: Phase II CAPTIVATE Study Update on Ibrutinib Plus Venetoclax in CLL

Case Report of COVID-19 Infection Unmasking CLL

Use of Ibrutinib During COVID-19–Induced Respiratory Failure in CLL: Case Study

Novel Mutation and CLL Resistance to BTK and SYK Inhibition: Case Study

Exploring Rapid Dose Escalation of Venetoclax in Patients With CLL

Personalizing Management of CLL: From the Advanced Practitioner Perspective

Can LCK Deletion Result in Acceleration of CLL?

Comparing Front-Line Treatments in CLL: Focus on Acalabrutinib